Invivyd (IVVD) Other Non-Current Assets (2021 - 2026)
Invivyd's (IVVD) quarterly Other Non-Current Assets came in at $1.2 million in Q2 2026, up 7740.0% on a YoY basis from $15000.0 in Q2 2025, and up 969.09% quarter-over-quarter from $110000.0 in Q4 2025.
Analysis
Invivyd (IVVD) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Other Non-Current Assets for 6 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets rose 7740.0% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (up 7740.0% YoY), and the FY2025 full-year result was $110000.0, up 223.53% from the prior year.
- Other Non-Current Assets grew to $1.2 million in Q2 2026 per IVVD's latest filing, from $110000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7.5 million in Q3 2024 and bottomed at $6000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $844823.5 across 5 years, with a median of $236000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets tumbled 99.92% in 2025, then surged 7740.0% in 2026.
- Over 5 years, Other Non-Current Assets stood at $191000.0 in 2022, then fell by 8.38% to $175000.0 in 2023, then tumbled by 80.57% to $34000.0 in 2024, then soared by 223.53% to $110000.0 in 2025, then soared by 969.09% to $1.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $110000.0, and $6000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 1.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 175,000.00 |
| Sep 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 291,000.00 |
| Mar 31, 2023 | 291,000.00 |
| Dec 31, 2022 | 191,000.00 |
| Sep 30, 2022 | 236,000.00 |
| Jun 30, 2022 | 299,000.00 |
| Mar 31, 2022 | 237,000.00 |
| Dec 31, 2021 | 3.30 Mn |
| Sep 30, 2021 | 6.12 Mn |